test

David Kim

@Paradigm Biocapital Advisors Lp

Latest period2024 - Q3ReportedManaged Assets$2.956BTotal holdings31
Assets growth rate13.13%Assets growth rate (2-Q avg)2.56%Continuous growth in asset value1 quarters

Portfolio positions

This chart displays the top 10 holdings in Paradigm Biocapital Advisors Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 31 positions.

Assets under management

The assets under management (AUM) of Paradigm Biocapital Advisors Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 2.956B in assets, with a quarterly growth rate of 13.13% and a 2-quarter average growth rate of 2.56%. The portfolio is managed by David Kim, and others.

Portfolio holdings

CurrentNew PositionIncreasedDecreasedExited
InvestmentPortfolio %Reported Value
IMTXImmatics N.v
Recent Activity
Increased 14.12%
1.51%
$44.554M
3.905M shares@ $11.41 avg price
APGEApogee Therapeutics Inc
Recent Activity
Increased 112.68%
1.4%
$41.225M
701,817 shares@ $58.75 avg price
IMVTImmunovant Inc
Recent Activity
1.32%
$38.854M
1.363M shares@ $28.52 avg price
CGEMCullinan Therapeutics Inc
Recent Activity
Increased 50.45%
1.32%
$38.854M
2.321M shares@ $16.75 avg price
SYRESpyre Therapeutics Inc
Recent Activity
New Position
1.27%
$37.28M
1.268M shares@ $29.41 avg price
PLRXPliant Therapeutics Inc
Recent Activity
New Position
1.18%
$34.801M
3.104M shares@ $11.21 avg price
KROSKeros Therapeutics Inc
Recent Activity
New Position
1.04%
$30.489M
525,037 shares@ $58.08 avg price
ERASErasca Inc
Recent Activity
Increased 47.15%
0.99%
$29.124M
10.668M shares@ $2.74 avg price
ORKAOruka Therapeutics Inc
Recent Activity
New Position
0.6%
$17.639M
719,660 shares@ $24.52 avg price
CATXPerspective Therapeutics Inc
Recent Activity
0.42%
$12.278M
919,692 shares@ $13.35 avg price